|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||19.27 - 19.27|
|52-week range||16.50 - 21.51|
|Beta (5Y monthly)||0.39|
|PE ratio (TTM)||16.06|
|Forward dividend & yield||1.10 (5.63%)|
|Ex-dividend date||19 Aug 2021|
|1y target est||N/A|
Dr. Calvin Sun, The Monsoon Diaries Founder & CEO, Clinical Assistant Professor and Attending Physician in Emergency Medicine in NYC, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
(Bloomberg) -- Consumer DNA testing giant 23andMe Holding Co. agreed to purchase telehealth upstart and drug-delivery service Lemonaid Health Inc. in a bid to make its personalized genetics approach part of patients’ primary care. Most Read from BloombergThe Top Money Maker at Deutsche Bank Reaps Billions From SingaporeWhy Americans and Britons Are Rushing to Buy Idyllic Homes in ItalyCities' Answer to Sprawl? Go Wild.Forget Palm Springs—Santa Fe Is the New Mecca for Modern ArchitectureOne of Ca
What happened Shares of the genetic-testing company 23andMe (NASDAQ: ME) gained another 16% through Thursday's close this week, according to data from S&P Global Market Intelligence. The biotech's stock is now up by more than 34% over the past two weeks.